ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimal hepatic encephalopathy (MHE) is an underdiagnosed complication of liver cirrhosis, associated with progression to overt hepatic encephalopathy (HE). The Portosystemic Hepatic Encephalopathy Score (PHES) is the recommended diagnostic standard, but its use is hindered by resource constraints and limited accuracy. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are released during neuroaxonal and astrocyte injury and may serve as HE-biomarkers. We investigated NfL and GFAP in cerebrospinal fluid (CSF) and serum across the spectrum of HE and assessed their correlation and diagnostic performance.
methodsIn this cross-sectional study, 35 patients with cirrhosis and 14 healthy controls (HC) were included. MHE was defined as PHES < -4, and overt HE was graded according to the West Haven Criteria. NfL and GFAP were quantified in CSF and serum using single-molecule array technology.
resultsNfL concentrations in CSF and serum increased stepwise from HC to unimpaired patients, MHE, and overt HE (p < 0.0001). CSF- and serum NfL were strongly correlated (rho = 0.888, p < 0.0001), and CSF and serum NfL discriminated MHE and overt HE from unimpaired patients and HC, with AUROCs of 0.877-0.902 and 0.930-0.951, respectively. GFAP showed moderate correlation between CSF and serum (rho = 0.496, p < 0.0004) and discriminatory value in CSF (AUROCs of 0.777-0.800); however, to a lesser extent than NfL.
conclusionNeuroaxonal injury is detectable in HE by NfL in both CSF and serum. The strong CSF and serum correlation suggests that serum NfL may serve as a minimally invasive biomarker of MHE and overt HE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.